Moderate alopecia areata (AA) research hub

B7981110 A Phase 3, randomized, double blind, placebo controlled study to investigate the safety and efficacy of ritlecitinib in adult and adolescent participants 12 years of age and older with moderate alopecia areata

This clinical trial is testing a medicine called ritlecitinib for moderate alopecia areata, a condition that causes patchy hair loss. Researchers want to find out if taking this daily tablet helps hair grow back over 24 weeks, while checking how safe and well tolerated it is.